While other biomarkers such as tumor size and Ki-67 levels are commonly used to predict lymph node metastasis, NLR offers a non-invasive, cost-effective alternative with a robust predictive value for cN0 HR(+) breast cancer patients. This evidence concerns the gene MKI67 and metastatic malignant neoplasm in the lymph nodes.